tiprankstipranks
Trending News
More News >
Tourmaline Bio, Inc. (TRML)
:TRML
US Market

Tourmaline Bio (TRML) AI Stock Analysis

Compare
540 Followers

Top Page

TR

Tourmaline Bio

(NASDAQ:TRML)

Rating:45Neutral
Price Target:
Tourmaline Bio's overall stock score reflects substantial financial and profitability challenges. While the technical indicators suggest some positive momentum, the negative P/E ratio and lack of dividend yield indicate valuation concerns. The strong equity position is a positive, but is overshadowed by the company's significant cash flow issues and lack of revenue growth.
Positive Factors
Clinical Trials
Pacibekitug demonstrates competitive efficacy and safety with key differentiation via less frequent dosing compared to competition.
Safety Profile
Paci shows a lower rate of infections and serious infections with its 50mg dose compared to a competitor's dose, indicating a favorable safety profile.
Negative Factors
Regulatory and Market Risks
Risks include failure of pacibekitug in clinical trials, failure to secure regulatory approval in the U.S., failure to achieve commercial success due to market size, penetration rate, and/or competition, and potential dilution risk.

Tourmaline Bio (TRML) vs. SPDR S&P 500 ETF (SPY)

Tourmaline Bio Business Overview & Revenue Model

Company DescriptionTourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.
How the Company Makes MoneyTourmaline Bio makes money primarily through the development and commercialization of its proprietary biologic therapies. The company generates revenue by licensing its technology and products to larger pharmaceutical firms, entering into strategic partnerships that provide upfront payments, milestone payments, and royalties on future sales. Additionally, Tourmaline Bio might receive funding from government grants and research collaborations that support its drug development efforts. As its pipeline matures, the company also aims to benefit from direct sales of its approved therapies.

Tourmaline Bio Financial Statement Overview

Summary
Tourmaline Bio faces significant financial challenges, particularly in profitability and cash flow management. Despite maintaining a strong equity position with low leverage, ongoing losses, negative cash flow, and minimal revenue generation present substantial hurdles.
Income Statement
30
Negative
Tourmaline Bio's income statement reflects a challenging financial environment. The company has a gross profit margin of 25% for the TTM, but significant negative EBIT and EBITDA margins indicate operating difficulties. The net profit margin is also negative, at -207,172.5% for TTM. The absence of revenue in previous periods and a minimal revenue in the current period highlight growth challenges.
Balance Sheet
45
Neutral
The balance sheet shows a relatively strong equity position with a debt-to-equity ratio of 0.0007 for TTM, indicating low leverage. However, the return on equity is negative due to ongoing losses, and the equity ratio is robust at 97.34% for TTM. These metrics suggest financial stability but highlight profitability issues.
Cash Flow
20
Very Negative
Tourmaline Bio's cash flow analysis reveals significant challenges, with a negative operating cash flow to net income ratio and free cash flow to net income ratio for TTM. The free cash flow growth rate is also negative, indicating cash generation issues. These factors point to liquidity concerns and operational inefficiencies.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue40.00K0.000.000.000.000.00
Gross Profit10.00K0.00-33.00K-6.00K-623.00K-447.00K
EBITDA-98.47M-89.73M-45.38M-19.70M-46.88M-22.24M
Net Income-82.87M-73.21M-42.12M-19.70M-904.00-22.71M
Balance Sheet
Total Assets287.50M309.00M210.29M9.10M150.00K152.78M
Cash, Cash Equivalents and Short-Term Investments249.31M258.30M202.95M8.26M150.00K149.49M
Total Debt196.00K244.00K415.00K504.00K150.00K0.00
Total Liabilities7.63M8.95M5.25M28.83M376.00K4.77M
Stockholders Equity279.86M300.05M205.04M-19.73M-226.00K148.00M
Cash Flow
Free Cash Flow-84.04M-77.27M-28.14M-11.53M-42.42M-20.50M
Operating Cash Flow-84.02M-77.26M-28.08M-6.46M-39.99M-19.21M
Investing Cash Flow20.50M-194.31M3.84M-5.07M-96.39M-133.30M
Financing Cash Flow558.00K161.35M156.72M19.85M137.40M131.12M

Tourmaline Bio Technical Analysis

Technical Analysis Sentiment
Negative
Last Price16.19
Price Trends
50DMA
16.88
Negative
100DMA
15.67
Positive
200DMA
19.41
Negative
Market Momentum
MACD
-0.23
Positive
RSI
41.85
Neutral
STOCH
16.62
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TRML, the sentiment is Negative. The current price of 16.19 is below the 20-day moving average (MA) of 17.81, below the 50-day MA of 16.88, and below the 200-day MA of 19.41, indicating a bearish trend. The MACD of -0.23 indicates Positive momentum. The RSI at 41.85 is Neutral, neither overbought nor oversold. The STOCH value of 16.62 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TRML.

Tourmaline Bio Risk Analysis

Tourmaline Bio disclosed 63 risk factors in its most recent earnings report. Tourmaline Bio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Tourmaline Bio Peers Comparison

Overall Rating
UnderperformOutperform
Sector (46)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
61
Neutral
$463.46M165.872.52%25.02%
54
Neutral
$514.54M-204.78%44.92%-40.06%
46
Neutral
$544.65M0.71%91657.69%97.21%
46
Neutral
C$194.28M-4.22-8.60%2.64%13.54%-1.44%
45
Neutral
$415.90M-26.14%74.59%
43
Neutral
$907.64M-48.45%7.15%
34
Underperform
$410.77M-45.82%10.38%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TRML
Tourmaline Bio
16.42
3.12
23.46%
ZVRA
Zevra Therapeutics
9.74
5.25
116.93%
KROS
Keros Therapeutics
13.45
-28.23
-67.73%
ORIC
Oric Pharmaceuticals
10.80
2.30
27.06%
TALK
Talkspace
2.77
0.56
25.34%
ERAS
Erasca
1.44
-0.91
-38.72%

Tourmaline Bio Corporate Events

Product-Related AnnouncementsBusiness Operations and Strategy
Tourmaline Bio Updates on Clinical Progress and Outlook
Positive
Dec 10, 2024

Tourmaline Bio has released an updated corporate presentation detailing its progress and future plans, including significant clinical trial milestones for its lead product, pacibekitug. The company is well-financed, with cash expected to fund operations into 2027, positioning it to achieve key milestones that could enhance its market position and provide value to stakeholders.

Product-Related AnnouncementsBusiness Operations and Strategy
Tourmaline Bio Unveils Clinical Progress and New Indication
Positive
Dec 10, 2024

Tourmaline Bio announced key updates at its Investor Day, highlighting progress in its clinical trials and strategic priorities. The company reported over-enrollment in its Phase 2 TRANQUILITY trial and introduced a new indication for pacibekitug, abdominal aortic aneurysm, while planning further developments contingent on trial outcomes, positioning itself for potential expansion in cardiovascular inflammation treatment.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: May 04, 2025